Skip to main content
BEONE MEDICINES LTD. logo

BEONE MEDICINES LTD. — Investor Relations & Filings

Ticker · 688235 ISIN · CNE100005XT6 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 727 across all filing types
Latest filing 2023-10-31 Share Issue/Capital Cha…
Country CN China
Listing Shanghai Stock Exchange 688235

About BEONE MEDICINES LTD.

https://beonemedicines.com/

BEONE MEDICINES LTD. is a biopharmaceutical company focused on the research, development, and commercialization of innovative therapeutic solutions, primarily in the field of oncology. The company specializes in the discovery of targeted small molecule drugs and biologics designed to address unmet medical needs in cancer treatment. Its research and development pipeline emphasizes precision medicine, utilizing advanced molecular biology and medicinal chemistry platforms to identify novel drug candidates. BEONE MEDICINES LTD. aims to improve patient outcomes by developing high-efficacy, low-toxicity therapies that target specific genetic drivers of disease. The company maintains a strong focus on clinical-stage development and strategic collaborations to advance its portfolio of next-generation medicines.

Recent filings

Filing Released Lang Actions
港股公告：翌日披露报表
Share Issue/Capital Change Classification · 100% confidence The document is a disclosure report related to changes in issued share capital and/or share repurchases by the company 百濟神州有限公司, registered in the Cayman Islands. It references specific Hong Kong Stock Exchange Listing Rules (Main Board Listing Rule 13.25A and GEM Listing Rule 17.27A) which require disclosure of changes in issued share capital. The document details share issuance under a share award plan, share counts before and after issuance, and related notes. It also includes a confirmation statement by an executive director and chairman. The content is focused on share capital changes and disclosures thereof, not on financial results, management changes, or other report types. The document length is over 5,000 characters and contains detailed data on share issuance and repurchases. Therefore, it fits the category of Share Issue/Capital Change (SHA).
2023-10-31 Chinese
港股公告：翌日披露报表
Share Issue/Capital Change Classification · 100% confidence The document is a detailed disclosure report about changes in issued share capital and/or share repurchases by the company 百济神州有限公司, registered in the Cayman Islands. It references specific Hong Kong Stock Exchange Listing Rules (Main Board Listing Rule 13.25A and GEM Listing Rule 17.27A) which require disclosure of changes in issued share capital. The document includes detailed tables showing share issuance under share award plans, dates, share counts, prices, and percentage changes. It also contains confirmations from the company's executive director and CEO regarding the authorization and compliance of the share issuance. The document is not an announcement of a report publication but the actual disclosure itself with substantive data on share capital changes. This fits the definition of a Share Issue/Capital Change filing, which covers announcements regarding new share issues, stock splits, or other capital changes.
2023-10-30 Chinese
港股公告：审计委员会会议日期
Regulatory Filings Classification · 95% confidence The document is a short announcement (678 characters) from BeiGene, Ltd. stating the date of the Audit Committee meeting scheduled for November 10, 2023, to review and approve financial results for the three and nine months ended September 30, 2023. It does not contain any actual financial data or detailed reports but merely announces the upcoming meeting and the agenda. According to the 'Menu vs Meal' rule, such a short announcement about a meeting and report approval is not the report itself but an announcement related to the report. Therefore, it should be classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other categories.
2023-10-26 Chinese
百济神州有限公司自愿披露关于英国国家卫生与临床优化研究所推荐百悦泽（泽布替尼胶囊）用于治疗慢性淋巴细胞白血病成人患者的公告
Regulatory Filings Classification · 95% confidence The document is a voluntary disclosure announcement by BeiGene Ltd. regarding the recommendation by the UK's National Institute for Health and Care Excellence (NICE) for the company's drug BeiYueZe (Zebutinib capsules) for treatment of chronic lymphocytic leukemia. It contains no financial statements, no regulatory filings, no voting results, no management changes, no earnings data, and no detailed financial or operational report. The document is an announcement about a regulatory/market development related to the company's product and potential commercial impact, including risk warnings to investors. The document length is 2039 characters, which is short and consistent with an announcement rather than a full report. It does not fit into categories like Annual Report, Earnings Release, or Regulatory Filings (which are more formal compliance documents). It is best classified as a Regulatory Filings (RNS) type, which is the fallback for miscellaneous regulatory announcements that do not fit other categories.
2023-10-20 Chinese
港股公告：翌日披露报表
Share Issue/Capital Change Classification · 95% confidence The document is a detailed disclosure report about changes in issued share capital and/or share repurchases by the company 百濟神州有限公司, registered in the Cayman Islands. It references specific Hong Kong Stock Exchange Listing Rules (Main Board Listing Rule 13.25A and GEM Listing Rule 17.27A) which require disclosure of share capital changes. The document includes detailed tables of share issuance, dates, share counts, prices, and percentage changes. It also contains formal confirmations by the company's executive director and CEO regarding the authorization and compliance of the share issuances. The document length is 4002 characters, which is relatively short but contains substantive data on share capital changes, not merely an announcement or a link to a report. This matches the definition of a Share Issue/Capital Change filing, which covers announcements regarding new share issues, stock splits, or other capital changes. Therefore, the correct classification is SHA (Share Issue/Capital Change).
2023-10-19 Chinese
港股公告：证券变动月报表
Regulatory Filings Classification · 100% confidence The document is a monthly securities movement report for a listed issuer and its Hong Kong Depositary Receipts issuer under Chapter 19B of the Listing Rules. It details changes in registered capital, issued shares, share options, and confirmations related to share issuance and compliance with listing rules. The document is addressed to the Hong Kong Stock Exchange and includes detailed tables of share movements and confirmations by an executive director. It is not a financial report, earnings release, or management discussion but a regulatory filing reporting share capital changes and share issuance confirmations. The document length is about 4,812 characters, and it is a formal regulatory disclosure rather than a report or announcement of a report. Therefore, the appropriate classification is Regulatory Filings (RNS).
2023-10-19 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.